X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more
X4 Pharmaceuticals Inc (XFOR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.452x
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.452x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.82 Million) by net assets ($61.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
X4 Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ITI Limited
NSE:ITI
|
0.025x |
|
Guangzhou Echom Sci&Tech Co Ltd
SHE:002420
|
-0.042x |
|
Santa Cruz County Bank
OTCQX:SCZC
|
0.001x |
|
Sprout Social Inc
NASDAQ:SPT
|
0.054x |
|
Tibet Duo Rui Pharmaceutical Co.Ltd.
SHE:301075
|
N/A |
|
LDR Turizm AS
IS:LIDER
|
0.160x |
|
Ascencio (D)
BR:ASCE
|
0.050x |
|
Wabash National Corporation
NYSE:WNC
|
-0.156x |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +80.36% |
| 2018-12-31 | $21.60 Million | $-40.90 Million | -1.894x | -298.88% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -224.09% |
| 2016-12-31 | $-56.56 Million | $-21.64 Million | 0.383x | +21.40% |
| 2015-12-31 | $-34.32 Million | $-10.82 Million | 0.315x | -- |